Clinical trials: Shy-Drager Syndrome
Parkinson Disease, Multiple System Atrophy
Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy
The primary objective of this study is to assess the safety and tolerability of exidavnemab after multiple dosing versus placebo.
- Trial name
- EXIST (NCT06671938)
- Testing
- exidavnemab
- Where
- 7 sites in Poland, Spain
- Volunteers
- 38 people
- Sponsor
- BioArctic AB
Multisystemic Atrophy
Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study
Background: Multiple System Atrophy (MSA) is an atypical parkinsonian syndrome including cerebellar impairment and poor response to dopatherapy.
- Trial name
- MSAJOY (NCT01044992)
- Testing
- H215O PET, Levodopa
- Where
- 4 sites in France
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration
PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK
Progressive Supranuclear Palsy (PSP), Cortico-Basal Degeneration (CBD) and Multiple System Atrophy (MSA) are degenerative brain conditions for which there are currently no curative treatments.
- Conditions
- Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration, Multiple System Atrophy (MSA)
- Trial name
- PROSPECT-M (NCT02778607)
- Where
- United Kingdom
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University College, London
Parkinson Disease, Prodromal Stage
Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases.
- Conditions
- Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Basal Ganglia Diseases
- Trial name
- ALPHA-FIT (NCT07324330)
- Testing
- Increase of physical activity volume and intensity with the use of a motivational smartphone application
- Where
- Germany
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Spinal Cord Injuries (SCI), Orthostatic Hypotension, Dysautonomic
Cardiovascular Function and Response to Stimulation Within the First Year After Spinal Cord Injury
The study aims to explore how cardiovascular function changes in the first year after a spinal cord injury, and to see how different treatments, like spinal stimulation through the skin (transcutaneous spinal stimulation), affect…
- Conditions
- Spinal Cord Injuries (SCI), Orthostatic Hypotension, Dysautonomic, Cardiovascular, Transcutaneous Spinal Stimulation
- Trial name
- NCT06841198
- Testing
- spinal cord transcutaneous stimulation, Ice testing
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Progressive Supranuclear Palsy, Cortico Basal Degeneration
Utilisation of Health Services and Quality of Life in Patients With Atypical Parkinsonian Syndromes
The study will compare health care utilisation and quality of life for patients with progressive supranuclear palsy, corticobasal syndrome and multiple system atrophy in different parts of the region that our specialist clinic…
- Conditions
- Progressive Supranuclear Palsy, Cortico Basal Degeneration, Multiple System Atrophy
- Trial name
- UHSQOLAPS (NCT06645626)
- Where
- United Kingdom
- Volunteers
- 198 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy
Unstructured Eye Tracking as a Diagnostic and Prognostic Biomarker in Parkinsonian Disorders
Study Rationale: No accurate tests currently exist to diagnose Parkinson's disease (PD) and the conditions which mimic it (atypical parkinsonism) at a very early stage.
- Conditions
- Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration
- Trial name
- NCT05638477
- Testing
- Free-viewing eye tracking
- Where
- Ireland
- Volunteers
- 122 people
- Sponsor
- Conor Fearon
Multiple System Atrophy
Lithium in Multiple System Atrophy
The purpose of this study is to determine safety and tolerability of the treatment with lithium in Multiple System Atrophy. Moreover, clinical symptoms, neuronal loss, quality of life and depressive symptoms, will be considered…
- Trial name
- LAMU (NCT00997672)
- Testing
- Lithium Carbonate
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Federico II University
Frontotemporal Degeneration, Progressive Supranuclear Palsy
Cognitive Impairement In Frontotemporal Dementia
This is an observational study that aims to better understand the genetic causes of frontotemporal degeneration (FTD), Multiple Systems Atrophy (MSA), and Progressive Supranuclear Palsy (PSP).
- Conditions
- Frontotemporal Degeneration, Progressive Supranuclear Palsy, Multiple System Atrophy
- Trial name
- NCT03452956
- Testing
- None-Observation Only
- Where
- United States
- Volunteers
- 997 people
- Sponsor
- University of Pennsylvania
Supine Hypertension, Autonomic Failure
Treatment of Supine Hypertension in Autonomic Failure (CPAP)
Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension.
- Trial name
- NCT03312556
- Testing
- continuous positive airway pressure (CPAP)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vanderbilt University Medical Center
Multiple System Atrophy
Efficacy and Safety of Bilateral Cervical Lymphatic-Venous Anastomosis in the Treatment of Multiple System Atrophy
Multiple System Atrophy (MSA) is a rare and aggressive neurodegenerative disorder characterized by a combination of motor impairments, autonomic dysfunction, and cerebellar ataxia, with no currently available disease-modifying…
- Trial name
- NCT07036939
- Testing
- Immediate LVA, Delayed LVA
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Ruijin Hospital
Post Acute COVID-19 Syndrome, Long COVID
Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID
The main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms.
- Conditions
- Post Acute COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19 Recurrent
- Trial name
- DSBLongCOVID (NCT05638620)
- Testing
- stellate ganglion block with 0.5% bupivacaine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jonathann Kuo, MD
Parkinson Disease, Osteoporosis
Trial of Parkinson's And Zoledronic Acid
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and…
- Conditions
- Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism
- Trial name
- TOPAZ (NCT03924414)
- Testing
- Zoledronic Acid 5Mg/Bag 100Ml Inj
- Where
- 77 sites in United States
- Volunteers
- 2,721 people
- Sponsor
- California Pacific Medical Center Research Institute
Multiple System Atrophy (MSA)
Multiple System Atrophy Multidisciplinary Clinic
This is a prospective cohort study to examine the disease burden of multiple system atrophy and the impact of multidisciplinary care on quality of life and caregiver burden.
- Trial name
- NCT03811808
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Texas Southwestern Medical Center
Shy-Drager Syndrome, Orthostatic Hypotension
Droxidopa in Treating Patients With Neurogenic Hypotension
Please note that the continuation study can be found at http://clinicaltrials.gov/show/NCT00633880. RATIONALE: Neurogenic hypotension is a fall in blood pressure that occurs when one moves from a lying down to a standing position…
- Trial name
- NCT00004478
- Testing
- droxidopa
- Where
- United States
- Sponsor
- Icahn School of Medicine at Mount Sinai
Multiple System Atrophy, Parkinsonism
Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy
The prevalence of Multiple System Atrophy (MSA) is reported to be between 3.4 - 4.9 cases per 100,000 population. The estimated average incidence is 0.6 - 0.7 cases per 100,000 people per year.
- Conditions
- Multiple System Atrophy, Parkinsonism, Multiple System Atrophy, Parkinson Variant
- Trial name
- NCT04876326
- Testing
- Autologous Adipose Mesenchymal Stem Cell Implantation, Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation, Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation
- Where
- Indonesia
- Volunteers
- 15 people
- Sponsor
- Universitas Indonesia
Multiple System Atrophy
Study of Rifampicin in Multiple System Atrophy
The purpose of this study was to determine whether Rifampicin was effective in slowing or reversing the progression of multiple system atrophy (MSA).
- Trial name
- MSA (NCT01287221)
- Testing
- Rifampicin
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Phillip Low
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Multiple System Atrophy
Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System Atrophy
The purpose of conducting phase 1 trial is to evaluate the safety and tolerability of autologous bone marrow-derived mesenchymal stem cells(CS10BR05) in subjects with Multiple System Atrophy.
- Trial name
- NCT03265444
- Testing
- CS10BR05
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Corestemchemon, Inc.
PSP, CBD
Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders
The investigators aim to learn more about symptoms suggestive of a neurodegenerative process.
- Conditions
- PSP, CBD, PCA, LPA
- Trial name
- AND1 (NCT04680130)
- Testing
- C-11 PiB, AV1451 Tau, C-11 ER176
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Mayo Clinic